Skip to main content
Cboe BZX Real-Time Last Sale USD
Today's Change
Price Quote as of

Today's Trading

Day Low 51.72
Day High 53.49
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.


Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.


A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.


What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.


A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Bluebird Bio Inc Rises 1.13% on Heavy Volume: Watch For Potential Pullback
- Comtex SmarTrend(R) - Mon Oct 12, 12:26PM CDT
Comtex SmarTrend(R) - CMTX
Mon Oct 12, 12:26PM CDT
Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $57.74 to a high of $58.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $58.32 on volume of 91,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Researchers Look for New Ways to Boost Diagnostic Capabilities
- PR Newswire - PRF - Fri Oct 2, 8:00AM CDT
PR Newswire - PRF - CMTX
Fri Oct 2, 8:00AM CDT
, /PRNewswire/ -- The global cancer diagnostics market is of the more innovative segments of the global diagnostics industry today. Cancer is one of the leading causes of death across the world, and its prevalence has been growing at an alarmingly fast rate. Early detection is a key factor to successfully combat cancer. Although various screening procedures, such as lab tests, imaging, and endoscopy, enable disease detection at an early stage, there are certain risk factors posed by medical imaging. As a result, medical professionals and innovators are focusing on development of effective diagnostic and treatment solutions in order to increase early detection rates. And, overall, the global cancer diagnostics market size is expected to reach by 2026, according to a new report by Grand View Research, Inc., while exhibiting a CAGR of 7.0% during the forecast period. AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), Exact Sciences Corporation (NASDAQ: EXAS), Bluebird bio, Inc. (NASDAQ: BLUE), GlaxoSmithKline plc (NYSE: GSK), Exelixis, Inc. (NASDAQ: EXEL)
bluebird bio Announces European Medicines Agency's Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D(TM)) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)
- BusinessWire - Fri Oct 2, 4:00AM CDT
BusinessWire - CMTX
Fri Oct 2, 4:00AM CDT
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the European Medicines Agency (EMA) accepted the company's marketing authorization application (MAA) for its investigational elivaldogene autotemcel (eli-cel, Lenti-D(TM)) gene therapy for the treatment of patients with cerebral adrenoleukodystrophy (CALD). CALD is a fatal neurodegenerative disease primarily affecting young boys.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 51.45 +2.02% increase
on 10/02/20
Period Open:55.90
Price movement based on the high, low and last over the given period.
59.06 -11.12% decrease
on 10/12/20
-3.41 (-6.10%) decrease
since 09/28/20
3-Month 51.45 +2.02% increase
on 10/02/20
Period Open:65.76
Price movement based on the high, low and last over the given period.
68.39 -23.25% decrease
on 08/06/20
-13.27 (-20.18%) decrease
since 07/28/20
52-Week 38.95 +34.76% increase
on 03/17/20
Period Open:85.60
Price movement based on the high, low and last over the given period.
99.36 -47.17% decrease
on 01/17/20
-33.11 (-38.68%) decrease
since 10/28/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies